Ultragenyx
Manufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
60 Leveroni Ct, Novato, California, 9494...Phone Number
(415) 483-8800Website
www.ultragenyx.comRevenue
$717 MillionStock Symbol
RAREIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
2
2
1
1
1
About Ultragenyx
Ultragenyx is a biopharmaceutical company founded in 2010 that focuses on developing treatments for rare and ultra-rare genetic diseases. The company specializes in creating biologics and small-molecule therapeutics targeting specific genetic disorders with limited treatment options. Ultragenyx's product pipeline includes treatments for metabolic disorders, bone diseases, and enzyme deficiencies. The company operates globally with a strong presence in North America, Europe, and Asia, collaborating with research institutions and pharmaceutical partners to advance its clinical programs. Ultragenyx maintains a commitment to addressing the unmet medical needs of patients with rare genetic conditions through innovative therapeutic approaches.Explore more
Ultragenyx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ultragenyx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Ultragenyx had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Ultragenyx
Ultragenyx, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Ultragenyx has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ultragenyx has new funding data
Earning: See what the market has to say on Ultragenyx recently announced quarterly report
Product Launch: Get notified when Ultragenyx launches new products
Check out if Ultragenyx is spiking on competitors!
Recommended Actions
Find VP level buyers at Ultragenyx
Find more new buyers
Compare Similar Companies to Ultragenyx
Compare insights from companies similar to Ultragenyx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ultragenyx
$717M
1K - 5K
Public
$1.6B
2010
Howard HornChief Financial Officer & Executive VP, Corporate Strategy
$675.1M
1K - 5K
Private
$225M
2009
LM
Leslie MillingtonSenior Director, Business Strategy & Operations Chief of Staff
Company Profile Activity
Activity Insights
Ultragenyx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ultragenyx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ultragenyx.
Ultragenyx financials insights
Gather financial insights about Ultragenyx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$45M
2012
Series B
$75M
2014
Stock Offering
$126.4M
Stock Offering
$60.2M
2015
Stock Offering
$175.1M
Stock Offering
$286.6M
2016
Corporate Investment
$65M
2019
Stock Offering
$330M
2025
Other Financing Round
$400M
Ultragenyx Tech Stack
A closer look at the technologies used by Ultragenyx
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Pharmaceuticals
Person-Based
Pricing
Ultragenyx News & Media
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
At Week 96, participants across treatment and crossover groups experienced mean reduction in daily cornstarch intake of 61% while maintaining glycemic control, with most participants achieving reduction of at least 50%Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx EmplUltragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a August 19, 2026 6:00 PM EDTCompany...Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ultragenyx
Sign Up For FreeTo access detailed company insights
Ultragenyx is a biopharmaceutical company founded in 2010 that focuses on developing treatments for rare and ultra-rare genetic diseases. The company specializes in creating biologics and small-molecule therapeutics targeting specific genetic disorders with limited treatment options. Ultragenyx's product pipeline includes treatments for metabolic d... Read More
